Adicet Bio Inc

Adicet Bio, Inc. (NASDAQ: ACET) is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL).

Recent Business and Financial Updates

• Overview of Adicet Bio, Inc.’s Q1 2025 Performance and Strategic Updates: Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced its financial results and operational highlights for the first quarter ended March 31, 2025, on May 6, 2025. The company reported a net loss of USD 28.2 million, or USD 0.31 per basic and diluted share, compared to a net loss of USD 28.0 million, or USD 0.35 per share, in Q1 2024, with a slight decrease in research and development (R&D) expenses to USD 22.8 million from USD 23.9 million, driven by reduced costs in contract development manufacturing. General and administrative (G&A) expenses remained stable at USD 7.1 million, compared to USD 7.0 million in the prior year, while the cash position stood at USD 150.4 million, sufficient to fund operations into the second half of 2026, supporting its ongoing clinical programs.
• Advancements in Autoimmune Disease Programs: Adicet Bio made significant strides in its autoimmune disease portfolio, with the Phase 1 clinical trial of ADI-001 now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE), following an expansion in April 2025. The company plans to further include patients with systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS), and anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) in Q3 2025, with preliminary clinical data expected in the second half of 2025, subject to study site initiation and patient enrollment timelines. Additionally, in February 2025, the FDA granted Fast Track Designations to ADI-001 for refractory SLE with extrarenal involvement and SSc, accelerating its development pathway for these critical indications.
• Progress in Oncology with ADI-270 for ccRCC: Adicet Bio continued to advance its oncology pipeline, with ongoing patient enrollment in the Phase 1 clinical trial of ADI-270 for metastatic/advanced clear cell renal cell carcinoma (ccRCC), expecting preliminary clinical data in the second half of 2025. The company showcased ADI-270’s potential through preclinical data presentations, including an oral abstract at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting from May 13-17, 2025, in New Orleans, and posters at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting in March 2025. These presentations highlighted ADI-270’s anti-tumor activity in hematologic and solid tumor models, reinforcing the potential of Adicet’s gamma delta 1 CAR T cell therapy platform in addressing challenging cancer indications.
• Corporate Governance and Leadership Enhancement: On the corporate front, Adicet Bio strengthened its leadership by appointing Michael Grissinger to its Board of Directors in April 2025, bringing over four decades of expertise in biopharmaceutical business development, strategy, and M&A, with a focus on immunology. Mr. Grissinger’s extensive experience, including his roles on the boards of Aprea Therapeutics and several privately-held biotech firms, is expected to enhance Adicet’s strategic direction as it approaches key clinical milestones. This appointment underscores the company’s commitment to leveraging seasoned leadership to drive its pipeline forward and maximize the potential of its innovative therapy platform.
• Financial Position and Future Outlook: Adicet Bio’s financial position as of March 31, 2025, reflects a cash balance of USD 150.4 million, down from USD 176.3 million at the end of 2024, yet sufficient to fund operations into the second half of 2026, providing a runway for its anticipated clinical data readouts in 2H 2025. The company is nearing significant milestones with its two lead programs, ADI-001 and ADI-270, expecting preliminary Phase 1 data from at least six patients with a three-month follow-up in both trials, which could validate the efficacy of its allogeneic gamma delta T cell therapies. CEO Chen Schor expressed optimism about the platform’s potential to deliver best-in-class therapies for autoimmune diseases and cancer, supported by ongoing efforts to identify additional differentiated programs targeting PSMA and further autoimmune indications.

Technical Observation (on the daily chart):

The Relative Strength Index (RSI) over a 14-day period stands at a value of 34.67, near oversold zone, with expectations of upward momentum from the near important support zone of USD 0.45-USD 0.50. Additionally, the stock's current positioning is below both the 50-period SMA and 200-period SMA, which may serve as dynamic short to medium-term resistance levels.  

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘WATCH’ rating has been given for Adicet Bio, Inc. (NASDAQ: ACET) at the closing market price of USD 0.48, as of May 08, 2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 08, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.